An interventional study of Managements for NeuroFirst target bundle and Managements for institutional routine in Silent Brain Infarction, Neurocognitive Disorders and Cardiac Surgery, sponsored by Chinese Academy of Medical Sciences, Fuwai Hospital. Recruiting at 5 sites in China. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2025-11-24.
Sponsored by Chinese Academy of Medical Sciences, Fuwai Hospital · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies in Neurocognitive Disorders with a site in China — 13 open to participants now, 14 under way, 1 of them phase 3. Neurocognitive Disorders · China.
Among the 22 studies in Neurocognitive Disorders with a site in China, this one is the 4th largest by planned enrollment of the 15 interventional ones that give a count, is one of 2 that started in 2025, is one of 9 with no phase, reaches primary completion later than 7 of the 13 other live ones, and was the 16th registered.
275 studies on the registry are indexed under Neurocognitive Disorders; 91 are open to participants now.
Browse Neurocognitive Disorders studies →13 of the 22 studies in Neurocognitive Disorders with a site in China are open now. Recruiting first, the newest first:
XiaoLiang Wang · Sites in China
Ages 18+
Shanghai 10th People's Hospital · Sites in China
Ages 65+
Fujian Provincial Hospital · Sites in China
Ages 60+ · Healthy volunteers
First Affiliated Hospital of Wannan Medical College · Sites in China
Ages 18+
Zhejiang University · Sites in China
Ages 60–80 · Healthy volunteers
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 61 Neurocognitive Disorders studies recruiting now, 38 (62%) set no upper age limit and 2 (3%) stop at 75 or younger; 4 take children under 18; 17 take healthy volunteers.
This study: 60 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
First in 2013; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 912 is above the median of 80 across 175 interventional studies indexed under Neurocognitive Disorders.
Median enrollment 264 across the 15 interventional studies, 210 across the 7 observational. Of the 4 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 22 have an industry lead sponsor. The 10 most frequent:
Chinese Academy of Medical Sciences, Fuwai Hospital is the lead sponsor of 147 studies on the registry; 51 are open to participants now.
Chinese Academy of Medical Sciences, Fuwai Hospital has 3 studies filed under Neurocognitive Disorders — fewer than ten, so there is no comparison to draw.
7 of the studies in Neurocognitive Disorders with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06416514Fujian Provincial HospitalPersonalized Interventions Via Health Portraits in Mild Behavioral Impairment | 2026-12-30 |
| NCT07878676Chinese Academy of Medical Sciences, Fuwai HospitalImpact of Preoperative Mild Cognitive Impairment on Postoperative Delirium in Patients Undergoing Cardiac Surgery | 2027-01 |
| NCT07665099Xijing HospitalThe Effect of Esketamine on Postoperative Cognitive Function in Elderly Patients Undergoing Oral and Maxillofacial Surgery | 2027-01-15 |
| NCT07914803Peking University First HospitalIntranasal Dexmedetomidine-esketamine Combination and Postoperative Cognitive Recovery in Older Patients | 2027-06 |
| NCT07936929XiaoLiang WangGut Microbiota and Amino Acid Metabolism in Post-CPB Delayed Neurocognitive Recovery | 2027-08-31 |
Add all 7 to your calendar (.ics) → With an account.
Among the 22 studies in Neurocognitive Disorders with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
the purpose of the study is to investigate whether a combined anesthetic targets bundle, known as the NeuroFirst strategy, focused on neurological protection, can reduce the incidence of silent brain infarction (SBI) and perioperative neurocognitive disorders (PND) in patients undergoing cardiac surgery. Additionally, the trial will assess the safety of this strategy.
The NeuroFirst target bundle incorporates multiple parameters, including mean arterial pressure (MAP), bispectral index (BIS), regional cerebral oxygen saturation (rSO2), and arterial inflow temperature during cardiopulmonary bypass.
The primary question this study seeks to answer is: Does the NeuroFirst strategy reduce the incidence of SBI and PND in cardiac surgery?
To address this, researchers will compare the NeuroFirst strategy with routine institutional practices based on published guidelines. Participants will be randomly assigned to either the NeuroFirst group or the routine care group. All participants will undergo magnetic resonance imaging (MRI), be assessed using the Confusion Assessment Method (CAM) and the Montreal Cognitive Assessment (MoCA), and be followed for up to one year postoperatively.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Management for NeuroFirst target bundle
Other: Managements for NeuroFirst target bundle
Management for institutional routine in accordance with published guidelines
Other: Managements for institutional routine
In the intervention group, patient management aims to achieve the NeuroFirst target bundle, including 1) mean arterial pressure (MAP) 65-90 mmHg, 2) bispectral index (BIS) 40-60, 3) regional cerebral oxygen saturation (rSO2)≥ 60% , and 4) arterial inflow temperature \<37 ℃ and rewarming rate \< 0.5 ℃/min after exceeding 30℃ during CPB. To achieve this target bundle, pharmacologic agents, fluid resuscitation, blood transfusion, and other therapeutic modalities will be utilized. These interventions are guided by comprehensive intraoperative monitoring, including conventional hemodynamic monitoring, invasive or non-invasive cardiac output and vascular resistance assessments.
MAP, BIS, cerebral rSO2 and arterial inflow temperature during CPB rewarming, will be managed according to institutional routine in accordance with published guidelines.
the 7-day incidence of new-onset silent brain infarction (SBI)
New-onset silent brain infarction refers to newly developed cerebral infarctions detected on MRI, compared with the preoperative MRI, in the absence of any corresponding clinical symptoms of cerebral infarction.
Time frame: within 7 days postoperatively
Key Secondary Outcome: the 30-day incidence of perioperative neurocognitive disorders (PND)
The incidence of 30-day PND includes the incidence of postoperative delirium in hospital and perioperative neurocognitive disorders within 30 days after surgery
Time frame: within 30 days postoperatively
the 5-day incidence of postoperative delirium
the incedence of delirium evaluated by CAM/CAM-ICU
Time frame: within five days postoperatively
the 30-day incidence of new-onset overt stroke
Postoperative new-onset overt stroke was defined as any new ischemic or hemorrhagic cerebrovascular event after surgery with focal or global neurological (motor, sensory or cognitive) dysfunction lasting at least 24 h. And a broadened stroke definition also including neurological dysfunction of \<24 h duration with corresponding evidence of central nervous system hemorrhage or infarction (including pathological, imaging, or other objective evidence of cerebral, spinal cord or retinal focal ischemic injury in a defined vascular distribution).
Time frame: within 30 days postoperatively
the 1-year incidence of new-onset overt stroke
Postoperative new-onset overt stroke was defined as any new ischemic or hemorrhagic cerebrovascular event after surgery with focal or global neurological (motor, sensory or cognitive) dysfunction lasting at least 24 h. And a broadened stroke definition also including neurological dysfunction of \<24 h duration with corresponding evidence of central nervous system hemorrhage or infarction (including pathological, imaging, or other objective evidence of cerebral, spinal cord or retinal focal ischemic injury in a defined vascular distribution).
Time frame: within 1 year postoperatively
the 1-year incidence of perioperative neurocognitive disorders (PND)
the incidence of perioperative neurocognitive disorders (PND)
Time frame: within 1 year postoperatively
the 30-day composite incidence of major adverse events
Major adverse events refer to renal insufficiency, myocardial infarction, pulmonary embolism, seizure and all-cause mortality.
Time frame: within 30 days postoperatively
the 1-year composite incidence of major adverse events
Major adverse events refer to renal insufficiency, myocardial infarction, pulmonary embolism, seizure and all-cause mortality.
Time frame: within 1 year postoperatively
the 30-day incidence of transient ischemic attack (TIA)
TIA is defined as focal arterial ischemia with transient symptoms (lasting \<24 hours) and without evidence of infarction by pathology or imaging.
Time frame: within 30 days postoperatively
the 1-year incidence of transient ischemic attack (TIA)
TIA is defined as focal arterial ischemia with transient symptoms (lasting \<24 hours) and without evidence of infarction by pathology or imaging.
Time frame: within 1 year postoperatively
Length of stay (LOS) in intensive care unit (ICU)
Length of stay (LOS) in intensive care unit (ICU) postoperatively
Time frame: Perioperative
Length of stay (LOS) in hospital
Length of stay (LOS) in hospital postoperatively
Time frame: Perioperative
Hospitalization cost
Operative and postoperative hospitalization cost
Time frame: Perioperative
Plan to share: No — Individual participant data (IPD) will not be shared in order to protect participant privacy and confidentiality. Additionally, the consent obtained from participants does not include provisions for data sharing, in accordance with ethical guidelines and institutional policies.
Started Jul 2025 (actual). Primary completion is estimated for Oct 2027, 27 months after the start.
Of 80 non-industry interventional studies with no phase under Neurocognitive Disorders, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 46. This study's planned 27 months is close to that.
Counting every sponsor, half of 83 studies reached it within 27 months; a quarter within 15 and three quarters within 46.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Chinese Academy of Medical Sciences, Fuwai Hospital →